Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01381861 · ClinicalTrials.gov registry record · Phase 2
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 study of Primary Peritoneal Carcinoma and Fallopian Tube Carcinoma, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 7
- Study locations
NCT01381861: Completed Phase 2 study of Primary Peritoneal Carcinoma and Fallopian Tube Carcinoma, sponsored by Tracon Pharmaceuticals.
NCT01381861 is a Phase 2 study of Primary Peritoneal Carcinoma and Fallopian Tube Carcinoma that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 23 participants, below the 330-participant average among 20 other Primary Peritoneal Carcinoma trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01381861, a Phase 2 study of Primary Peritoneal Carcinoma and Fallopian Tube Carcinoma, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Primary Outcome
Number of patients ongoing within the study who have not progressed after 6 months of treatment
Conditions Studied
Interventions
- BIOLOGICAL Carotuximab (TRC105)
Study Locations (7)
California
- University of California, San Diego - La Jolla
- University of Southern California - Los Angeles
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Palm Beach Cancer Institute - West Palm Beach
Indiana
- Indiana University-Bren and Melvin Simon Cancer Center - Indianapolis
New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT01381861 record still lists
NCT01381861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 330-participant average among 20 other Primary Peritoneal Carcinoma trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Primary Peritoneal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Carotuximab (TRC105) is the first listed.
NCT01381861 lists 7 locations in 6 states (California, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT01381861 about?
NCT01381861 is a clinical study titled "Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma". The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
What is the current status of trial NCT01381861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2011-07. Estimated completion is 2013-12.
What conditions does trial NCT01381861 study?
This clinical trial studies the following conditions: Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent Ovarian Cancer.
What interventions are being tested in trial NCT01381861?
The interventions under investigation include: Carotuximab (TRC105) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01381861?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01381861 being conducted?
This trial has 7 study locations across Alabama, California, Florida, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Peritoneal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01381861's enrollment target sits among peer trials
23 19th of 20 higher than 2 of 20 other Primary Peritoneal Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Peritoneal Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia